• 1. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 2. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Dissolution of cork biopolymers in biocompatible ionic liquids
  Helga Garcia,Rui Ferreira,Marija Petkovic,Jamie L. Ferguson,Maria C. Leit?o,H. Q. Nimal Gunaratne,Luís Paulo N. Rebelo Green Chem., 2010,12, 367-369
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonic acids and derivatives Benzenesulfonate esters

Recent Advances in the Application of 2,2-Difluoroethyl P-Toluenesulfonate (CAS: 135206-84-7) in Chemical Biology and Pharmaceutical Research

2,2-Difluoroethyl p-toluenesulfonate (CAS: 135206-84-7) is a key intermediate in the synthesis of various fluorinated compounds, which have gained significant attention in pharmaceutical and agrochemical industries due to their unique physicochemical properties. This compound serves as a versatile building block for introducing the difluoroethyl group into target molecules, enhancing their metabolic stability and bioavailability. Recent studies have explored its utility in the development of novel therapeutics, particularly in the areas of kinase inhibitors and antiviral agents.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficient use of 2,2-difluoroethyl p-toluenesulfonate in the synthesis of next-generation Bruton's tyrosine kinase (BTK) inhibitors. The researchers successfully incorporated the difluoroethyl moiety into the inhibitor scaffold, resulting in improved pharmacokinetic properties and enhanced target engagement. The modified inhibitors showed promising results in preclinical models of autoimmune diseases and B-cell malignancies, with reduced off-target effects compared to previous generations of inhibitors.

In the field of antiviral drug development, a recent patent application (WO2023051234) disclosed novel nucleoside analogs synthesized using 2,2-difluoroethyl p-toluenesulfonate as a key reagent. These analogs exhibited potent activity against RNA viruses, including SARS-CoV-2 variants, by effectively inhibiting viral polymerase activity. The incorporation of the difluoroethyl group was found to significantly enhance membrane permeability while maintaining favorable safety profiles in cellular assays.

From a chemical biology perspective, researchers have developed innovative labeling strategies utilizing 2,2-difluoroethyl p-toluenesulfonate as a precursor for ¹⁸F-labeled probes. A 2024 study in Chemical Science reported a novel radiolabeling approach that enables efficient incorporation of ¹⁸F isotopes for positron emission tomography (PET) imaging. This advancement opens new possibilities for studying drug distribution and target engagement in vivo with improved spatial and temporal resolution.

The safety profile and handling considerations of 2,2-difluoroethyl p-toluenesulfonate have also been the subject of recent investigations. A comprehensive toxicological assessment published in Regulatory Toxicology and Pharmacology (2023) confirmed its acceptable safety margins for use in pharmaceutical manufacturing when proper containment measures are implemented. The study provided valuable data on occupational exposure limits and recommended handling procedures for industrial-scale applications.

Looking forward, the unique properties of 2,2-difluoroethyl p-toluenesulfonate continue to inspire innovative applications across multiple therapeutic areas. Current research directions include its use in PROTAC (proteolysis targeting chimera) technology and as a versatile handle for bioconjugation in antibody-drug conjugates. The compound's ability to modulate physicochemical properties while maintaining metabolic stability makes it particularly valuable in addressing current challenges in drug discovery and development.

• 433-06-7(2,2,2-Trifluoroethyl Tosylate)
• 93728-50-8(1-Propanol,3-[(4-methylphenyl)sulfonyl]-, 1-(4-methylbenzenesulfonate))
• 70628-05-6(2-Propanol, 1-fluoro-, 4-methylbenzenesulfonate)
• 113557-78-1(1,3-difluoropropan-2-yl 4-methylbenzene-1-sulfonate)
• 80-40-0(Ethyl p-toluenesulfonate)
• 6315-52-2(1,2-Bis(tosyloxy)ethane)
• 67674-48-0(Hexafluoroisopropyl Tosylate)
• 383-50-6(2-Fluoroethyl Tosylate)
• 312-68-5(3-Fluoropropyl Tosylate)
• 786-31-2(2,2,3,3-Tetrafluoropropyl 4-Toluenesulfonate)